Metabolic associated liver disease

被引:1
|
作者
Testino, Gianni [1 ,3 ]
Pellicano, Rinaldo [2 ]
机构
[1] Polyclin San Martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, ASL3 C-O, Genoa, Italy
[2] Molinette SGAS Hosp, Unit Gastroenterol, Turin, Italy
[3] Polyclin San martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, ASL3 C-O Padigl 10,Piazzale R Benzi 10, I-16132 Genoa, Italy
关键词
Alcohol drinking; Metabolic syndrome; Non-alcoholic fatty liver disease; Diabetes mellitus; type; 2; NONALCOHOLIC FATTY LIVER; ALCOHOL-USE; HEPATOCELLULAR-CARCINOMA; TRANSIENT ELASTOGRAPHY; BLOOD-PRESSURE; FIBROSIS; RISK; IDENTIFICATION; PERFORMANCE; MANAGEMENT;
D O I
10.23736/S0031-0808.22.04730-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In real practice the patient with liver disease is often the carrier of multiple etiological factors such as metabolic syndrome (MS) and alcohol consumption (AC). Their copresence is often underestimated and AC is not adequately studied. Traditionally to diagnose non-alcoholic fatty liver disease (NAFLD), AC must not exceed 30 gr for men and 20 gr for women per day. This limit should still be reduced, especially in relation to the AC and fibrogenesis ratio and also frequent misestimation of AC or unrecognized MS may underestimate multi caused liver injury. AC is a contributing cause of MS and alcoholic and non-alcoholic liver disease have a substantially overlapping histopathological picture. Moreover, AC and MS are cause and contributing cause of extra-hepatic morbidity and mortality. It can be concluded that the possible simplification of terminology at metabolic associated liver disease (MALD) makes clinical activity more usable and immediate, facilitates better communication and cooperation between scientific societies and specialists who apparently deal with different medical sectors, facilitates early identification of related hepatic and extra-hepatic pathology, allows to "see the person in a unitary way," to create more streamlined care pathways, to reduce the hospitalization rate with relative cost-benefit advantage and to create unitary prevention and health promotion policies.
引用
收藏
页码:555 / 563
页数:9
相关论文
共 50 条
  • [31] Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions
    Beygi, Mohammad
    Ahi, Salma
    Zolghadri, Samaneh
    Stanek, Agata
    NUTRIENTS, 2024, 16 (14)
  • [32] LIVER FIBROSIS IN ASIANS WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
    Kim, Byung Ik
    Sohn, Won
    Kwon, Heon-Ju
    Cho, Yong Kyun
    HEPATOLOGY, 2021, 74 : 1022A - 1022A
  • [33] Metabolic associated fatty liver disease: Addressing a new era in liver transplantation
    Madeleine G Gill
    Avik Majumdar
    World Journal of Hepatology, 2020, 12 (12) : 1168 - 1181
  • [34] Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease
    Sohn, Won
    Kwon, Heon-Ju
    Chang, Yoosoo
    Ryu, Seungho
    Cho, Yong Kyun
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) : E1135 - E1148
  • [35] Metabolic associated fatty liver disease: Addressing a new era in liver transplantation
    Gill, Madeleine G.
    Majumdar, Avik
    WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (12) : 1168 - 1181
  • [36] Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
    Suoh, Maito
    Esmaili, Saeed
    Eslam, Mohammed
    George, Jacob
    HEPATOLOGY INTERNATIONAL, 2024, 18 (06) : 1740 - 1755
  • [37] The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease
    Sogabe, Masahiro
    Okahisa, Toshiya
    Kagawa, Miwako
    Kashihara, Takanori
    Shinomiya, Ryo
    Miyake, Takanori
    Kawaguchi, Tomoyuki
    Yokoyama, Reiko
    Kagemoto, Kaizo
    Kida, Yoshifumi
    Okada, Yasuyuki
    Tomonari, Tetsu
    Kawano, Yutaka
    Sato, Yasushi
    Nakasono, Masahiko
    Takayama, Tetsuji
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (11-12) : 1587 - 1598
  • [38] Lipid Disorders and Metabolic-Associated Fatty Liver Disease
    Anwar, Shima Dowla
    Foster, Christy
    Ashraf, Ambika
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (03) : 445 - 457
  • [39] The microbial metabolome in metabolic-associated fatty liver disease
    Li, Mengci
    Rajani, Cynthia
    Zheng, Xiaojiao
    Jia, Wei
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (01) : 15 - 23
  • [40] Infections at the nexus of metabolic-associated fatty liver disease
    Joost Boeckmans
    Matthias Rombaut
    Thomas Demuyser
    Baptist Declerck
    Denis Piérard
    Vera Rogiers
    Joery De Kock
    Luc Waumans
    Koen Magerman
    Reinoud Cartuyvels
    Jean-Luc Rummens
    Robim M. Rodrigues
    Tamara Vanhaecke
    Archives of Toxicology, 2021, 95 : 2235 - 2253